NCT04791332View on ClinicalTrials.gov

A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

July 28, 2021

Study Completion Date

July 28, 2021

Conditions
Healthy
Interventions
DRUG

JNJ-67953964

JNJ-67953964 capsule will be administered orally.

DRUG

Placebo

Matching placebo will be administered orally.

Trial Locations (1)

130-0004

Sumida Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT04791332 - A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants | Biotech Hunter | Biotech Hunter